RxDoctor Payments Data

Sylvonne Cox, PA

Medical · Austell, GANPI 1992863385

Payments from drug & device makers

$9,620in general payments, 2019–2025

Across 436 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$977
  • Sanofi$901
  • Grifols USA, LLC$467
  • Amgen$447
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,35197%
  • Education$2693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,620 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$27,704
Medicare patients
202
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter250$204,179
Dupixent PenDupilumab12$47,129
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$46,236
Breo ElliptaFluticasone/Vilanterol92$44,270
Spiriva RespimatTiotropium Bromide51$28,679
Spiriva HandihalerTiotropium Bromide39$23,570
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$20,637
SymbicortBudesonide/Formoterol Fumarate62$18,543
EliquisApixaban23$13,369
Fluticasone-SalmeterolFluticasone Propion/Salmeterol80$10,808
Albuterol Sulfate HfaAlbuterol Sulfate324$9,473
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,338
XareltoRivaroxaban11$7,912
Advair HfaFluticasone Propion/Salmeterol18$7,423
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$5,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,342$273,588390 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$977$70,708135 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,103$37,01869 claims
PfizerEliquis$17$13,36923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.

Other medical in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →